Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.
|27 Oct 2021||$1.62||$-0.01||-0.61%||1,585,953||$1.64||$1.66||$1.60|
|26 Oct 2021||$1.64||$-0.02||-1.21%||1,601,905||$1.67||$1.69||$1.64|
|25 Oct 2021||$1.66||$-0.03||-1.78%||1,090,435||$1.70||$1.71||$1.65|
|22 Oct 2021||$1.69||$0.01||0.60%||1,273,945||$1.68||$1.71||$1.67|
|21 Oct 2021||$1.68||$0.02||1.20%||1,793,046||$1.69||$1.69||$1.65|
|20 Oct 2021||$1.66||$0.02||1.22%||2,931,541||$1.69||$1.73||$1.66|
|19 Oct 2021||$1.64||$0.03||1.88%||2,306,334||$1.60||$1.65||$1.58|
|18 Oct 2021||$1.60||$0.00||0.00%||1,756,399||$1.63||$1.65||$1.59|
|15 Oct 2021||$1.60||$0.03||1.91%||1,310,944||$1.58||$1.60||$1.58|
|14 Oct 2021||$1.57||$0.03||1.94%||1,386,248||$1.55||$1.58||$1.54|
|13 Oct 2021||$1.55||$0.04||2.66%||1,352,042||$1.51||$1.56||$1.51|
|12 Oct 2021||$1.51||$-0.02||-1.31%||1,436,405||$1.52||$1.53||$1.50|
|11 Oct 2021||$1.53||$-0.02||-1.30%||1,764,600||$1.55||$1.55||$1.52|
|08 Oct 2021||$1.54||$0.01||0.65%||1,772,793||$1.56||$1.56||$1.53|
|07 Oct 2021||$1.53||$0.02||1.32%||2,673,226||$1.53||$1.56||$1.51|
|06 Oct 2021||$1.52||$-0.03||-1.94%||3,449,090||$1.57||$1.59||$1.51|
|05 Oct 2021||$1.55||$-0.07||-4.35%||4,559,723||$1.61||$1.63||$1.54|
|04 Oct 2021||$1.61||$-0.02||-1.22%||1,765,318||$1.64||$1.65||$1.61|
|01 Oct 2021||$1.64||$-0.04||-2.38%||1,358,209||$1.66||$1.67||$1.63|
|30 Sep 2021||$1.68||$0.02||1.20%||1,048,369||$1.68||$1.69||$1.66|
|29 Sep 2021||$1.66||$-0.02||-1.19%||1,573,193||$1.67||$1.67||$1.64|
|28 Sep 2021||$1.68||$-0.03||-1.76%||937,448||$1.71||$1.72||$1.68|
|07 Jul 2021||Silviu Itescu||Issued||1||$2,412,000||
Issue of options.
|Mr Michael Robert Spooner||Non-Executive Director||Sep 2004||
Mr Spooner has served on the board of directors in capacities at Australian and international biotechnology companies, including BiVacor Pty Ltd (2009-2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). He is the chairman of Simavita Limited since May 2016 and Chairman of MicrofuidX since February 2018. Mr Spooner has had spend much of his career internationally where he served in roles including as a partner to PA Consulting Group and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition He has owned and operated companies providing services and has had consult to a number of U.S. and Asian public companies. He provides executive management, business strategy and accounting expertise as well as had establish relationships with investment firms and business communities around the world. He is a Chair of the Risk Committee.
|Professor Silviu Itescu||Chief Executive OfficerExecutive Director||Jun 2004||
Dr Itescu has had establish an reputation in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He has been a faculty Member of Columbia University in New York, and of Melbourne and Monash universities in Australia. Dr Itescu has consulted for pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of publicly listed life sciences companies.
|Mr Donal Paul O'Dwyer||Non-Executive Director||Sep 2004||
Mr O'Dwyer has over 25 years of experience as a executive in the cardiovascular and medical devices industries. From 1996 to 2003, he has had work for Cordis Cardiology, the cardiology division of Johnson & Johnson's Cordis Corporation, as its president (Europe) and from 2000 as its worldwide president. Prior, Mr O'Dwyer had work with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. He is on the board of directors of a number of life sciences companies including Cochlear Limited, Fisher & Paykel Healthcare Ltd and NIB Holdings Ltd. With his experience as a executive and a director, as well as his experience in the cardiovascular and medical devices industries, he provides business, science, engineering and management expertise. He was a former Non-executive Director of CardieX Ltd (since 2004 - 2019). He is a member of the Risk Committee.
|Dr Eric A Rose||Non-Executive Director||Apr 2013||
Dr Rose is currently Executive Chairman of SIGA Technologies. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 through 1992, he led the Columbia Presbyterian heart transplantation program in the United States. Dr Rose currently sits on the board of directors of ABIOMED. His experience as a surgeon, researcher and businessman provides medical, pharmaceutical, scientific and industry expertise.
|Mr William (Bill) A Burns||Non-Executive DirectorVice-Chairman||Mar 2014||
Mr. Burns has had spend his management career at the Beecham Group and F. Hoffmann-La Roche Ltd. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he served the board of directors of F. Hoffmann-La Roche Ltd until 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp from 2014 until its sale to Acorda Therapeutics Inc in 2016. Mr Burns is also a Member of the Oncology Advisory Board of the Universities of Cologne/Bonn in Germany. In 2014, he was serving as a trustee of the Institute of Cancer Research, London, and from March 2016 until April 2020 a Governor of The Wellcome Trust in London, UK. His experience in the pharmaceutical industry, as a Member of the board of directors of other pharmaceutical companies, provides pharmaceutical, healthcare, industry, leadership and management expertise.
|Mr Joseph R Swedish||Non-Executive DirectorNon-Executive Chairman||Jun 2018||
Mr Swedish has more than four decades of healthcare leadership experience serving United States healthcare enterprises. He is the co-founder and a partner at Concord Health Partners. Mr Swedish was Chairman, President and Chief Executive Officer of Anthem, Inc.(2013 - 2018) and he served as a Senior Adviser (2018 - 2020). Prior, Mr Swedish was CEO for healthcare delivery systems, including Trinity Health and Centura Health. Currently, he sits on the Board of Directors of IBM Corporation, CDW Corporation and Centrexion Therapeutics. Mr Swedish is past Chairman of Duke University's Fuqua School of Business Board of Visitors and is a current Member. Previously, he was Chairman of the Catholic Health Association and America's Health Insurance Plans (AHIP). His experience as a leader in the US healthcare sector with twenty-five years as CEO, in resource allocation and reimbursement metrics, provides industry, leadership and management experience. He is a member of the Risk Committee.
|Ms Shawn Cline Tomasello||Non-Executive Director||Jul 2018||
Ms Tomasello has more than 30 years experience in the pharmaceutical and biotech industries. Since 2015, Ms Tomasello has been Chief Commercial Officer at immuno-oncology cell therapy company Kite Pharma, where she played a role in the company's acquisition in 2017 by Gilead Sciences. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc. Ms Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she had manage product revenues, and was in expansion and acquisition strategies. She has also held positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms Tomasello currently serves on the Board of Directors of Principia Biopharma, Inc., Abeona Therapeutics, Inc., Gamida Cell, Ltd. and UroGen Pharma, Ltd. She previously served on the Board of Clementia Pharmaceuticals, Inc. and Diplomat Specialty. Her experience in the pharmaceutical and biotech industries provides industry, leadership and management expertise.
|Mr Philip J. Facchina||Non-Executive Director||Mar 2021||
Mr Facchina has more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr Facchina has been Chief Strategy Officer at SurgCenter Development (SurgCenter), managing the company's strategic relationships, including its relationships with the US ambulatory surgical centers (ASC) market and its constituents. Prior to SurgCenter, Mr Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr Facchina led the technology, media, and communications and healthcare investment banking groups of FBR Capital Markets. Mr Facchina currently serves as an independent director for ViON Corporation and MilltechFX, and is Advisor to the CEO of Johanna Foods Inc. Previously, among other directorships and committee posts, Mr Facchina served on the Board of Web.com (Nasdaq:WEB), where he led Corporate Governance.
|Mr Charlie Harrison||Company Secretary||Sep 2014||
|Ms Niva Sivakumar||Joint Company Secretary||Oct 2019||
|Josh Muntner||Chief Financial Officer||
|Fred Grossman||Chief Medical Officer||
|Dagmar Rosa-Bjorkeson||Chief Operating Officer||
|Charlie Harrison||Company Secretary||
|Peter Howard||General Counsel||
|John McMannis||Head of Manufacturing||
|Geraldine Storton||Head of Regulatory Affairs and Quality Management||
|Paul Simmons||Head of Research and New Product Development||
|Niva Sivakumar||Joint Company Secretary||
|Eric Strati||Pharma Partnering||
|Michael Schuster||Pharma Partnering||
|J P Morgan Nominees Australia Pty Limited||107,438,069||18.32%|
|HSBC Custody Nominees (Australia) Limited||103,290,771||17.61%|
|Professor Silviu Itescu||67,751,838||11.55%|
|Citicorp Nominees Pty Limited||13,318,990||2.27%|
|UBS Nominees Pty Ltd||11,101,280||1.89%|
|National Nominees Limited||10,653,027||1.82%|
|Independent Asset Management Pty Limited||7,870,558||1.34%|
|BNP Paribas Nominees Pty Ltd||6,203,700||1.06%|
|Merrill Lynch (Australia) Nominees Pty Limited||6,084,737||1.04%|
|BNP Paribas Nominees Pty Ltd i||4,986,283||0.85%|
|Dalit Pty Ltd||4,828,839||0.82%|
|Mr Gregory John Matthews & Mrs Janine Marie Matthews||3,956,219||0.67%|
|CA Third Nominees Pty Limited||3,832,425||0.65%|
|Dalit Pty Ltd i||2,195,000||0.37%|
|Citicorp Nominees Pty Limited i||2,077,360||0.35%|
|Kentgrove Capital Pty Ltd||2,000,100||0.34%|
|BNP Paribas Noms Pty Ltd||1,908,014||0.33%|
|HSBC Custody Nominees (Australia) Limited Gsco Eca||1,784,018||0.30%|
|LALP Pty Ltd||1,647,144||0.28%|
|BNP Paribas Nominees Pty Ltd ii||1,645,043||0.28%|